教學人員
何永樂教授
助理教授
PhD in Neuroscience (HKU), FIBMS(UK), MRSB (UK)
- ST506
- +852 3400 8966
- philip-wl.ho@polyu.edu.hk
ORCID ID
SCOPUS ID
Google Scholar簡歷
何永樂教授分別於1997年和1999年在香港科技大學獲得生物化學學士和哲學碩士學位。並於2004年在香港大學內科學系獲得博士學位。在加入香港理工大學之前，何教授曾在香港大學擔任博士後，研究助理教授和科學主任。
何教授的臨床前研究重點是主要圍繞柏金遜症及其相關的多種神經系統疾病，包括使用體外和體內實驗模型闡明與LRRK2突變相關的線粒體功能障礙和自噬受損的致病機制，以開發新的神經保護策略。除了自主研發的LRRK2突變小鼠模型外，他還開始製備柏金遜症患者來源的誘導多能幹細胞作為疾病替代模型。此外，何教授還作為項目負責人與海洋污染國家重點實驗室（SKLMP，CityU）合作研究新興化學品（CECs）的環境風險。2015年他開發了一種新型的基於人類細胞的檢測試劑盒，用於評估環境異雌激素和各種內分泌干擾化合物誘導的雌激素效應。這種新型檢測採用了一種自主研發的蛋白標記作為試劑盒的主要檢測成分。這項發明已在美國、歐洲和中國獲得了專利。
何教授在著名國際期刊中發表了50多篇研究論文和邀請評論，包括《Autophagy》, 《npj Parkinson’s disease》, 《Translational Neurodegeneration》等。何教授作為PI / Co-I獲得了HMRF和RGC / GRF的多項科研資助，並負責指導神經科學碩士和博士研究生的學習和實驗室工作。此外，何教授還積極參與研究社區服務，被邀請擔任一些著名期刊的編委、編委會成員和審稿人，包括《Nature Communications》、《Translational Neurodegeneration》、《Journal of Neurology》、《Brain and Behavior》以及《Frontiers in Molecular Neuroscience》。
學歷
- Doctor of Philosophy (PhD): Dept of Medicine, The University of Hong Kong
- Master of Philosophy (MPhil) in Biochemistry, The Hong Kong University of Science and Technology
- Bachelor of Science (BSc) in Biochemistry, The Hong Kong University of Science and Technology
專業資格
- Fellow - Institute of Biomedical Science, United Kingdom (since Jan 2021)
- Professional member (Explorer) - Society of Environmental Toxicology and Chemistry (SETAC Asia-Pacific) - a global, non-profit professional organization dedicated to the advancement of environmental science and management (since Jun 2024)
- Member – Society for Neuroscience (SfN), USA (since Nov 2025)
- Member – The Royal Society of Biology, United Kingdom (since Jan 2026)
- Full member – State Key Laboratory of Marine Environmental Health (SKLMEH), City University of Hong Kong, Hong Kong (since Oct 2022)
- Principal Investigator - Research Centre for Chinese Medicine Innovation (RCMI), The Hong Kong Polytechnic University, Hong Kong SAR, China (since May 2025)
- Principal Investigator - Mental Health Research Centre, PolyU Academy for Interdisciplinary Research, The Hong Kong Polytechnic University, Hong Kong SAR, China (since Jan 2024)
- Principal Investigator - Research Institute for Smart Ageing, The Hong Kong Polytechnic University, Hong Kong SAR, China (since Apr 2024)
研究興趣
研究成果
- Choi ZYK, Liu HF, Chang EES, Pang SYY, Luo LY, Ruan Y, Wang Q, Malki Y, Zhang SXY, Weng KY, Lau BWM, Ng RCL, Zhang Z, Ho SL, Ho PWL*. Long-term oral glucocerebrosidase activator reduces soluble α-synuclein oligomer accumulation in parkinsonian LRRK2 mutant mouse brain npj Parkinsons disease. 2025; 11:359 doi.org/10.1038/s41531-025-01205-7.
- Tang W, Chen B, Ho PWL, Zheng Q, Nga CTY, Zhu Z, Leung GKK*, and Kiang KM*. Activation of chaperone-mediated autophagy suppresses glioblastoma by promoting wild-type IDH1/isocitrate dehydrogenase 1 (IDH1) degradation. Autophagy 2025; 30:1-21. doi.org/10.1080/15548627.2025.2589906.
- Ng MHF, Lam JWY, Choi ZYK, Liu H, Ho PWL, Lau BWM and Yee BK*. Affective Phenotypes in Heterozygous LRRK2 R1441G Knock-In mice. Frontiers in Genetics. 2025; 16:1629897. doi: 10.3389/fgene.2025.1629897.
- Kwok JYY*, Chan LML, Lai CA, Ho PWL, Choi ZYK, Auyeung M, Pang SYY, Choi EPH, Fong DYT, Yu DSF, Lin CC, Walker R, Wong SY, Ho RTH. Effects of meditation and yoga on anxiety, depression and chronic inflammation in patients with Parkinson's disease: A randomised clinical trial. Psychotherapy and Psychosomatics. 2025; 94(2):101-118. doi: 10.1159/000543457.
- Chang EES, Liu HF, Choi ZYK, Malki Y, Zhang SXY, Pang SYY, Kung MHW, Ramsden DB, Ho SL, Ho PWL*. Loss of mitochondrial Ca2+ response and CaMKII/ERK activation by LRRK2R1441G mutation correlated with impaired depolarization-induced mitophagy. Cell Communication and Signaling. 2024; 22:485. doi.org/10.1186/s12964-024-01844-y.
- Kwok JYY*, Auyeung M, Pang SYY, Ho PWL, Yu DSF, Fong DYT, Lin CC, Walker R, Wong SY, Ho RTH. A randomized controlled trial on the effects and acceptability of individual mindfulness techniques - meditation and yoga - on anxiety and depression in people with Parkinson's disease: a study protocol. BMC Complement Med Ther. 2023; 23(1):241. doi: 10.1186/s12906-023-04049-x.
- PWL Ho*, LF Li, HF Liu, ZYK Choi, EES Chang, SYY Pang, Y Malki, CT Leung, MHW Kung, DB. Ramsden, SL Ho*. In vivo overexpression of synaptogyrin-3 (SYNGR3) promotes striatal synaptic dopamine uptake in LRRK2R1441G mutant mouse model of Parkinson’s disease. Brain and Behavior. 2023; 13:e2886. doi:10.1002/brb3.2886.
- PWL Ho*#, EES Chang#, CT Leung, HF Liu, Y Malki, SYY Pang, ZYK Choi, Y Liang, WS Lai, Y Ruan, KMY Leung, S Yung, JCW Mak, MHW Kung, DB. Ramsden, SL Ho*. Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain α-synuclein oligomers without adverse effects. npj Parkinsons disease. 2022; 8:115. doi:10.1038/s41531-022-00386-9.
- Li L#, Ho PWL#, Liu HF, Pang SYY, Chang EES, Choi ZYK, Malki Y, MHW Kung, Ramsden DB, Ho SL*. Transcriptional Regulation of the Synaptic Vesicle Protein Synaptogyrin-3 (SYNGR3) Gene: The Effects of NURR1 on Its Expression. International Journal of Molecular Sciences 2022; 23(7):3646. doi:10.3390/ijms23073646.
- Chang EES, Ho PWL*, Liu HF, Pang SYY, Leung CT, Malki Y, Choi ZYK, Ramsden DB, Ho SL*. LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease. Translational Neurodegeneration 2022; 11:10. https://doi.org/10.1186/s40035-022-00285-2.
- Pang SYY, Lo RCN, Ho PWL, Liu HF, Chang EES, Leung CT, Malki Y, Choi ZYK, Wong WY, Kung MHW, Ramsden DB, Ho SL*. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Translational Neurodegeneration 2022; 11:5. doi:10.1186/s40035-022-00281-6.
- Klinosky DJ*, … Ho PWL, Ho SL, Leung CT, Liu HF, Pang SY, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy 2021; 17(1):1-382. (doi:10.1080/15548627.2020.1797280).
- Liu HF#, Ho PWL#, Leung CT, Pang SY, Chang EES, Choi ZYK, Kung MHW, Ramsden DB, Ho SL*. Aberrant mitochondrial morphology and function associated with impaired mitophagy and DNM1L/ERK signaling are found in aged mutant Parkinsonian LRRK2R1441G mice. Autophagy 2021; 17(10):3196-3220. (doi: 10.1080/15548627.2020.1850008).
- Ho SL*, Ho PWL, Siu DCW. Parkinson disease and leucine-rich repeat kinase 2 gene mutation: abridged secondary publication. Hong Kong Med J 2020; 26(Suppl 8): S22-6.
- Ho PWL, Leung GC, Liu HF, Pang SY, Lam CS, Xian JW, Li LF, Kung MHW, Ramsden DB, Ho SL*. Age-dependent accumulation of oligomeric a-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Autophagy 2020; 16(2):347-370. (doi: 10.1080/15548627.2019.1603545).
- Pang SY, Ho PWL, Liu HF, Leung GC Li LF, Chang EES, Ramsden DB, Ho SL*. The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease. Translational Neurodegeneration 2019; 8:23. (doi:10.1186/s40035-019-0165-9).
- Human Catechol-O-methyltransferase (COMT) Assay [European Patent Office (EPO): EP2328909A1] - Listed inventor
- Human Catechol-O-methyltransferase (COMT) Assay [United State Patent & Trademark Office (USPTO): US20100081147A1] - Listed inventor
- Human Catechol-O-methyltransferase (COMT) Assay [China Cooperation Treaty (PCT): CN102203119A] - Listed inventor
